Member Info for PM2022

Forgot to mention Hakkaido in June as well. Crazy period of incoming news.

The pressure of news on many fronts is building up. When so much pressure builds up then an explosion happens.

Before June votes for jobs we have all these news very likely due.

1) Barcelona SPV.
2) 301 update
3) lab contracts
4) New compound to be added. It was stated we would get about 4 a year and we have not had one for about 14 months.
5) 201 deal completed or an update before votes.
6) FInancials

You can bet they will come out firing over the next few weeks. 201 and Barcelona the big ones. A great time to buy before the ride up starts imo.

Looks like someone is desperate to buy in cheaper despite claims he has shares at 11 p. A bit obvious.

Placings from the old management are irrelevant and now we only have 100 million shares. Most AIM stocks do placings so don't see an issue with it but as long as it's controlled and done at decent prices not at single digits.

By my calculations if they can seal the 201 deal in the coming months, Barcelona and some lab updates then a £5 million placing at 25p range would mean we have about 120-125 million shares. That along with warrants, 201 payments and revenue should see us through to our first deal. They could use 0.5 million to pay for the asset 2 from one of the payments. Asset 3/4 is a long term plan and once they strike gold they can then build.

Look at other stocks such as REDX 335 million shares and they got to £1, It's possible we could only have 150 million shares by the time we get our first preclinical deal. The key is to not do the next placing below 20p.

Having at least 2/3 in SPV will make it very likely we get a late stage preclinical or a huge preclinical deal in the next 2 years. Moving from 10p to 200/300p with some II on board then it's a no brainer both short term and long term and a life changer. Going for potential rather than chasing rainbows is the way forward.

I think if they can't get to the 20 p range by June then it might be best to make a few changes as we need confidence levels to change and we can't have another dilution at the low prices.

Great posts last week from Adam.

Looking forward to the next 6 weeks. I would say it's arguably the most important in Val's history given the share price, the work done so far and the voting for positions in June. Lots of news expected from 10p so we should have a fantastic few weeks for sure.

Reposted for those that missed it as it covers many important points. 3/3

Yes; I would like a resolution to 201.

The Company would be in a better financial position without the LOI, and I believe that it has shot trust in the BOD, rightly or wrongly, to such a degree that it needs to be addressed head-on.

This could be in the form of a payment to maintain exclusivity, or to maintain ongoing costs to VAL (e.g. patent renewal), which are not free. For an outfit wishing to raise multiple millions, this is token.

At very minimum, we should receive a reasonable update (we are past "in due course", in my opinion).

The initial payment would ultimately only be a few hundred grand, but 201 has probably wiped 15-20M from our MCap. It's a one-way "no win, no fee" arrangement, and it has been terrible for shareholders.

If the above couldn't be done, then I'd move on; even if it mean't going back for more work, as has been done for 301.

This is my opinion. The BOD feel differently, may have seen more than we know, and are adamant that it's on, so if it is (realistically it would have to be soonish, by even the largest stretches), then any ultimate successes are totally on them.

However, if the deal is delayed further, and ultimately is not signed, then that's on them, too.

But we have Kevin, Stella, Martin, Gerry, and a financial advisory team who have agreed, in due dil terms, that TX are going to be giving VAL money. It's a board-collective decision, and this is as much in their remit as that if the CEO. They've asked us to trust them.

Let's see how this develops in the next couple of months.

Reposted for those that missed it as it covers many important points. 2/3

The other point to note, is that they only seem to take on an SPV when the formulation is right and the efficacy/pharmacodynamics look promising.

So, whilst any delays are incredibly frustrating as a SH, if any pass these, then they have much more promise than an otherwise lead-generated test material. It's essentially optimised, and to get to that stage in a large pharma could cost 10-15 Million quid.

VAL are good at cost-cutting in this, and seem to do it on a fairly narrow shoe-string.

So, ultimately, you could argue that CLX might be "valued" at 15-20p as is, all these months in, and that any additional SPV could be 10p each, at signature.

But I don't want to annoy the converse posters, so I'll just say that I *personally* think that 10p significantly undervalues the one SPV we have, without considering anything else like the lab; 301; 3M in the bank; the cost of the VAL "shell"; work undertaken with two more evaluations etc.

But I do strongly disagree with the line "it takes years for commercialisation", as that simply isn't true. There are other AIM Biopharma outfits with milestone deals in place for compounds at an earlier stage than CLX001 currently is, wherein formal drug development work had not yet started at contract stage (just concept).

PatientInvestor I also concur strongly with. I do not want to see a negative impact of 201 on any future good news, nor do I think that it is an appropriate time to dilute for growth. The reason for this is that there is a lot currently in the VAL tank, and this should be maximised throughout 2023 with the tools to hand.

Reposted for those that missed it as it covers many important points. 1/3

So - be on the look out for the dosing of healthy animals.

They seem to have nailed the pharmacology and efficacy aspects of a submission, so this is a third hurdle to pass.

Personally, I'd also like to see more efficacy data, in a larger number of animals/tumours.

I'd be publishing any of the above, if only in the form of a poster. This would allow any developments to be RNS'd efficiently, and allow momentum to build. If I have one criticism of the excellent work they've done with CLX, and the excellent and scientifically-prolific partner they have chosen, it is that VAL as an outfit underestimates the thirst for scientific news, by the average retail investor.

This gives the impression that VAL are working as an academic science department, rather than a share-holder owned public company, but ironically without the scientific output (201 peer reviewed data and BC201 delays, as examples). It's a shame, as they can do the *hard* part very well, from all the evidence I've seen, so I see it as a personal objective to keep pressing the BOD hard to deliver data, but in a commercially-aware manner. This is a gap that I think needs improvement, but that is better than the converse.

SAR got to about a 200-oddM Mcap at one stage, as excitement built regarding SDC-1801 and the final stages of preclinical tox testing, helped by a couple of HNWI deciding to chip in. Obviously it has fallen for reasons beyond the scope of this post a lot since (regulatory preclinical development issues, which VAL should be wise to try and foresee/avoid), but the fundamentals of a potential great Phase 1 drug should not be underestimated. I'd take 70p a share for a comparable CLX001 price if it gets to Phase 1-ready; never mind £2.36 :-)

Every Phase 1 SPV, to my mind, would be the same, looking at the therapy areas and potential markets available.

I think the above is probably fairly pragmatic feedback for the BOD. No point just continually sticking the knife in, and especially no point with pathetic child-like strops around how the CEO dresses, or looks. Totally debases any form of criticism; at least in my view. Plus it makes the poster look like big willy.

It was an extension. That is just maximum deadline that they working towards. The difference is that the experiments are being done in our lab now. Big difference but hard to say.

Porky, I seriously don't think you understand placings and risks. Clearly you never learnt from DDDD where you kept buying all the way down thinking it is cheap. You forgot to look at the cash burn rate of 52 million a year in that stock and also it had debt and forgot a placing would not support any working capital. If you were depending on third party payments then that is unreliable.

First of all 5p would be a market cap of 5 million. By then we should have Barcelona as SPV and few lab contracts and further news on other drugs like Hokkaido and 301 even if people think 201 will not get done. You can twist it all you want but that would not be worth 5 p more like 30 p and if we still are 10 p I seriously doubt much discount will be offered.

Second point and this is where you seem to lack knowledge. 5 p placing for say 5 million would be a dilution of about 100 million extra shares. That would mean huge stock and if VAL is burning say 3/4 million with a market cap of just 5 million then unless it goes up big from that point then the stock becomes more risky due to a low market cap and high dilution rates for any future raise and any upwards movements becomes difficult at those price.

The cheapest price and best price to buy VAL is 10 p range. We have lots of news due and hopefully we should move to 20p and above more if 201 gets done. The DIlutions would be less and far more upside with less stock.

You're just looking at the SP price but you don't have a clue about finances. Partly why you got screwed in DDDD so best try and use some common sense.

He doesn't get everyone can see the desperation from him to buy and will want to hold even more. It shows the value on offer and at some stage hopefully we will see a strong rise.

Anyway the new ISA year is tomorrow so when news comes soon we should move a decent amount.

I would refer to the Cenkos report published after resolution on 4 March 2023.

The first lab was needed and was a big positive. For little cost it will allow us to take on work for revenue, increase speed of evaluation projects, save money on projects and should allow Institutional investment as and when revenue starts coming through. This should see a significant increase in SP.

Only part is Asset 2 but they know how we feel regarding that and they stated they will build then buy in the recent presentation and many options for that such as getting an II in at a premium price. It's a long term plan but one that can result in a really positive increase in share price if done at the right times and would allow large investments from II.

The board needs to release a statement to stop false rumours once for all. The best approach in my view is:
1) release statement
2) BOD buys some shares
3) Get news out.

It's down to them how they play it but I am sure it will work out. We are a great price and once things turn I expect a fairly large increase in a short space of time.

It's all relative if we had a large phase two trial we would be worth a few hundred million already but for what we have it's worth 10s million just on that alone with a deal if concluded.

Don't forget trials were done at the lower dosage so % success is actually greater than 54.5 %. To be confirmed from larger trials but safe and effective as below.

· The headline results released in the Company announcement on 28 September 2020 highlighted the response rate of 54.5%, where response was confirmed by a lack of disease progression by PCWG2 (Prostate Cancer Working Group 2) criteria. The dataset now received provides the detailed breakdown of this by providing both the PSA modulation afforded by the treatment, and the tumour response.

Although if we move to 30p plus after 201 then a takeover could be possible.

I don't think anyone here would fall for that. You need to do better than that rubbish. It just suits your agenda to try and buy at a price you will never get. PYC is the only thing you know so you have to speculate using that.

Suzy to hit with some decent news soon and we move to 20p plus. Barcelona/201 next.

The new ISA year is only two days away. Good time to get some news out in the new financial year to encourage some investment.

I always felt it would be beneficial to get Barcelona out close with 201 news to avoid a drop back down so we shall see how it plays out.

If it's bad it is likely priced at these prices. 10 million market cap. We have CLX001, 301, lab, 201 and likely Barcelona and possibly Hokkaido and some decent cash. Any one of these is worth more than our MC or will be shortly if Barcelona or Hokkaido come good. We should be significantly higher but I'll leave that to everyone else to decide. I was invested even 65 p and posting but that does not mean I did not purchase from single digits. FACTS.

Therefore we can agree to disagree. Enjoy your day.

OK LD. No need to keep repeating the same points. You don't know my average and I have remained consistent with my views and unless you can prove we are NOT undervalued and have plenty of news due then I need not say anything more. I have made numerous attempts to prove why we are undervalued. Have a nice day.

Just remember DYOR. One or two here just want you to sell so they can buy cheaper but in reality they win and you lose if you sell because of the fear that some try and create. I am more determined to keep hold so they don't get a chance. Ignore sentiment and look at the fundamentals.

Look at all pharmas across AIM. Most have far more stock than VAL. Val only has 100 million shares and excellent control of finances. This is helped by the fact we don't do clinical trials and this is where most pharmas burn the most cash. We will also shortly be generating revenue.

1) Hemo 900 million shares in issue and a share price of 2p and was recently 4p but NINE times more shares than VAL but far less potential.
2) REdX 32p but were stable in the 60s. 335 more shares in issue. VAL only has 100 million. Although they have a deal and are further than VAL though I would argue we have more potential given the SPV we have coming through.
3) Synairgen 8p but 201,374,975 shares in issue. VAL only has 100 million. but again we have more potential with new SPVs coming through and more likelihood of early stage deals which can be very rewarding.

The list goes on. DYOR.

Therefore my point is don't let others scare you. We have enough cash and value. Lots of news due and that should take us to 20,30p and more short term and personally i think 201 will get done soon taking us much higher. At 20/30p later in the year, it's hardly a dilution given our cash burn rate therefore look at the value on offer.

A great buy at 10p. In 1/2 years this could be £1/£2 very easily and although we may have 200 million shares in issue by then it is nothing if we keep progressing. A life changer in the long run for those that can buy during these times imo. DYOR.

Stick to fundamentals and don't let others scare you. Buy when others are fearful as Warren Buffet says.

I would say over the next two years VAL has about 100 million shares to play with but within that I would expect a deal with huge upfront payment and milestone payments and I think £1-£2 is a dead cert if we can control dilutions and get a deal. Even if we don't get a deal by then, we have revenue to be generated shortly and SPVs and we should see a significant return from 10p. Some may wish to wait but the issue with that is you will not get 10p but more likely be buying at 30/40p or more. So the real multibagger is from here both short and long term.

Thank you for the support. Have a nice day. :)

Kevin,

If you want to get the point then sell out and buy back at 4p.

The guy wants you to turn that 15.4p into 1.54p. If you want to believe all that then sell out but the truth is you know the company should be worth more and is likely to go up so that is why you hold. Therefore you disagree with him.

Regards,

SP